3 Papers
Bin He is an academic researcher from Chinese Center for Disease Control and Prevention. The author has contributed to research in topics: Internal medicine & Azacitidine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
Jun Li,Qi Han,Yan Huang,Yanhui Wei,Jie Zi,Li-Dong Zhao,Zhimei Cai,Xuzhang Lu,Rong Xiao,Yanming Zhang,Xiao Yang,Hao Xu,Naitong Sun,Wanchuan Zhuang,Zhengdong Wu,Yuan chen Xia,Yanli Xu,Bin He,Wei Zhu,Fengling Min,Yongchun Chen,Banghe Ding,Pei Shi,Jing Xie,Hua Tang,Zefa Liu,Bingzong Li,Yu Sun,Hongxia Qiu,Limin Duan,Elanora Dovat,Chunhua Song,Laszlo Szekely,Sinisa Dovat,Zheng Ge +34 more
TL;DR: It is reported that HHT in combination with cytarabine, aclarubicin/daunorubi- cin (HAA/HDA) achieved a higher CR than the standard “ 3 + 7 ” regimen (DA) in treating de novo AML.
High Efficacy of Azacitidine Plus Hag in Acute Myeloid Leukemia: A Multi-Center, Phase 2 Clinical Trial
Jun Ding Li,Qi Han,Yan Huang,Yanhui Wei,Jie Zi,Li-Dong Zhao,Zhimei Cai,Xuzhang Lu,Rong Xiao,Yanming Zhang,Xiao Yang,Hao Xu,Naitong Sun,Wanchuan Zhuang,Zhengdong Wu,Yuan chen Xia,Yanli Xu,Bin He,Wei Zhu,Fengling Min,Yongchun Chen,Banghe Ding,Pei Shi,Jing Xie,Hua Tang,Zefa Liu,Bingzong Li,Yu Sun,Hongxia Qiu,Limin Duan,Chunhua Song,Zheng Ge +31 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of adding Aza to the HAG regimen for acute myeloid leukemia (AML) in a multi-center, single arm, phase 2 clinical trial.
A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
Rong-cheng Li,Lirong Huang,Jia Li,Zhaojun Mo,Bin He,Yunpeng Wang,Xiaohong Wu,Maria Minutello,Françoise Guinet-Morlot,Sylvie Pichon +9 more
TL;DR: PVRV-NG was shown to be as immunogenic as Verorab in each age range in the per-protocol and full analysis sets and showed that both vaccines have similar safety profiles.